Cancer Diagnostics Solutions
Von Willebrand Factor (vWF) is a large multimeric glycoprotein localized to endothelial cells, circulating plasma, and platelet ?-granules. It functions as a carrier for coagulation Factor VIII and facilitates platelet adhesion and aggregation at sites of vascular injury. VWF undergoes multiple posttranslational modifications including propeptide cleavage and N-terminal disulfide bond formation that modulate its conformation, multimeric assembly, and binding affinity for Factor VIII. Immunohistochemical detection of vWF is utilized to confirm endothelial cell lineage in lesions of ambiguous histogenesis, such as Kaposi sarcoma and cardiac myxoma. It is commonly employed within a panel of vascular markers to distinguish vascular neoplasms from those of non-vascular origin. However, vWF expression is not uniformly retained in all endothelial-derived tumors
Factor XIIIa is a plasma transglutaminase integral to the blood coagulation cascade, crucial for stabilizing fibrin networks at injury sites to form clots.
Factor XIIIa is a plasma transglutaminase integral to the blood coagulation cascade, crucial for stabilizing fibrin networks at injury sites to form clots. It is expressed in platelets, megakaryocytes, fibroblast-like cells of the placenta, uterus, and prostate, as well as in monocytes, macrophages, and dermal dendritic cells. Anti-Factor XIIIa immunohistochemistry is employed to identify fibrohistiocytic neoplasms, such as dermatofibromas.
Fascin is a 55-kDa actin-bundling protein that plays a critical role in the regulation of cell migration. It is frequently upregulated in a wide range of human carcinomas, where its overexpression has been associated with enhanced metastatic potential. Fascin demonstrates high sensitivity in labeling Reed?Sternberg cells, making it a valuable diagnostic marker for classical Hodgkin?s lymphoma
Friend leukemia integration 1 transcription factor (FLI-1) is a protein encoded by the proto-oncogene FLI-1. The FLI-1 protein plays a critical role in the pathogenesis of Ewing sarcoma/peripheral primitive neuroectodermal tumor (ES/pPNET). Normally, FLI-1 is expressed in endothelial cells and hematopoietic cells, including T-lymphocytes. Immunohistochemical detection of the FLI-1 protein has proven valuable in distinguishing ES/pPNET from most of its potential mimics. ES/pPNET is a rare primary tumor of the bone and soft tissue that resembles other undifferentiated tumors.
FOXA1, also referred to as hepatocyte nuclear factor 3-alpha, belongs to the forkhead box (FOX) family of transcription factors. It was originally identified as a hepatocyte-enriched regulator essential for the transcription of genes such as transthyretin and ?1-antitrypsin. More recently, FOXA1 has been recognized as a critical modulator of estrogen receptor (ER) signaling and endocrine responsiveness in breast carcinoma. Its expression shows strong correlation with ER positivity, particularly within luminal A subtype breast cancers, a molecular phenotype associated with favorable clinical outcomes.
FOXP3, also referred to as scurfin, is a transcription factor belonging to the forkhead/winged-helix family of proteins and plays a pivotal role in the development, maintenance, and suppressive function of regulatory T cells (Tregs). In Treg-specific cellular models, FOXP3 binds to the promoter regions of numerous genes essential for Treg-mediated immunoregulatory functions and can act as a transcriptional repressor upon T cell receptor (TCR) engagement.
Dysregulation in the frequency or function of FOXP3-expressing Tregs has been associated with various pathological conditions. In the tumor microenvironment, there is often a relative enrichment of FOXP3+ regulatory T cells, which contributes to an immunosuppressive milieu that facilitates immune evasion by malignant cells.
Follicle-stimulating hormone (FSH) is a hormone produced and released by gonadotropic cells in the anterior pituitary gland. In females, FSH promotes the maturation of immature ovarian follicles, aiding in their development to a mature state. As the follicle matures, it secretes inhibin, which in turn reduces FSH production. In males, FSH stimulates the Sertoli cells in the testes to produce androgen-binding protein, playing a vital role in sperm production (spermatogenesis). FSH and luteinizing hormone (LH) work together to support reproductive processes.
FSH antibodies are valuable markers for classifying pituitary tumors and studying pituitary-related diseases, as they specifically react with cells that produce FSH.
Human follicle-stimulating hormone (hFSH) is a glycoprotein hormone with a molecular mass of approximately 35.5 kDa, commonly purified from the urine of postmenopausal women. It functions as a heterodimer composed of two non-covalently associated subunits: a 165-amino acid alpha (?) subunit, which is common among glycoprotein hormones and biologically inactive on its own, and a hormone-specific beta (?) subunit consisting of 115 amino acids, which confers biological specificity and receptor-binding activity
Fumarate Hydratase (FH), also known as fumarase, is a mitochondrial enzyme integral to the tricarboxylic acid (TCA) cycle, catalyzing the reversible conversion of fumarate to malate. Immunohistochemically, FH exhibits strong expression in mitochondria-rich normal tissues such as renal and hepatic parenchyma. Germline pathogenic variants in the FH gene are causative of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), a cancer predisposition syndrome characterized by cutaneous and uterine leiomyomas and a highly aggressive form of renal cell carcinoma. FH deficiency in tumors can be assessed by immunohistochemistry, serving as a diagnostic tool in HLRCC-associated neoplasms. FH-deficient pheochromocytomas (PCCs) and paragangliomas (PGLs), although underrecognized, can be reliably identified via loss of FH expression on IHC. These neoplasms are strongly associated with germline missense mutations in FH, yet they are rarely accompanied by leiomyomas or renal cell carcinoma, indicating a possible genotype-phenotype correlation. Emerging evidence suggests that FH-deficient PCCs/PGLs may carry an elevated risk of metastatic progression.